Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging

Joseph F. Poduslo, Thomas M. Wengenack, Geoffry L. Curran, Thomas Wisniewski, Einar M. Sigurdsson, Slobodan I Macura, Bret J. Borowski, Clifford R Jr. Jack

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Smart molecular probes for both diagnostic and therapeutic purposes are expected to provide significant advances in clinical medicine and biomedical research. We describe such a probe that targets β-amyloid plaques of Alzheimer's disease and is detectable by magnetic resonance imaging (MRI) because of contrast imparted by gadolinium labeling. Three properties essential for contrast enhancement of β-amyloid plaques on MRI exist in this smart molecular probe, putrescine-gadolinium-amyloid-β peptide: (1) transport across the blood-brain barrier following intravenous injection conferred by the polyamine moiety, (2) binding to plaques with molecular specificity by putrescine-amyloid-β, and (3) magnetic resonance imaging contrast by gadolinium. MRI was performed on ex vivo tissue specimens at 7 T at a spatial resolution approximating plaque size (62.5 μm3), in order to prove the concept that the probe, when administered intravenously, can selectively enhance plaques. The plaque-to-background tissue contrast-to-noise ratio, which was precisely correlated with histologically stained plaques, was enhanced more than nine-fold in regions of cortex and hippocampus following intravenous administration of this probe in AD transgenic mice. Continuing engineering efforts to improve spatial resolution are underway in MRI, which may enable in vivo imaging at the resolution of individual plaques with this or similar contrast probes. This could enable early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.

Original languageEnglish (US)
Pages (from-to)315-329
Number of pages15
JournalNeurobiology of Disease
Volume11
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Amyloid Plaques
Magnetic Resonance Imaging
Gadolinium
Amyloid
Molecular Probes
Putrescine
Clinical Medicine
Polyamines
Blood-Brain Barrier
Intravenous Injections
Intravenous Administration
Transgenic Mice
Noise
Biomedical Research
Early Diagnosis
Hippocampus
Alzheimer Disease
Peptides
Therapeutics

ASJC Scopus subject areas

  • Neurology

Cite this

Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. / Poduslo, Joseph F.; Wengenack, Thomas M.; Curran, Geoffry L.; Wisniewski, Thomas; Sigurdsson, Einar M.; Macura, Slobodan I; Borowski, Bret J.; Jack, Clifford R Jr.

In: Neurobiology of Disease, Vol. 11, No. 2, 2002, p. 315-329.

Research output: Contribution to journalArticle

Poduslo, JF, Wengenack, TM, Curran, GL, Wisniewski, T, Sigurdsson, EM, Macura, SI, Borowski, BJ & Jack, CRJ 2002, 'Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging', Neurobiology of Disease, vol. 11, no. 2, pp. 315-329. https://doi.org/10.1006/nbdi.2002.0550
Poduslo, Joseph F. ; Wengenack, Thomas M. ; Curran, Geoffry L. ; Wisniewski, Thomas ; Sigurdsson, Einar M. ; Macura, Slobodan I ; Borowski, Bret J. ; Jack, Clifford R Jr. / Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. In: Neurobiology of Disease. 2002 ; Vol. 11, No. 2. pp. 315-329.
@article{0942acfb46e349178fb93907785d081e,
title = "Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging",
abstract = "Smart molecular probes for both diagnostic and therapeutic purposes are expected to provide significant advances in clinical medicine and biomedical research. We describe such a probe that targets β-amyloid plaques of Alzheimer's disease and is detectable by magnetic resonance imaging (MRI) because of contrast imparted by gadolinium labeling. Three properties essential for contrast enhancement of β-amyloid plaques on MRI exist in this smart molecular probe, putrescine-gadolinium-amyloid-β peptide: (1) transport across the blood-brain barrier following intravenous injection conferred by the polyamine moiety, (2) binding to plaques with molecular specificity by putrescine-amyloid-β, and (3) magnetic resonance imaging contrast by gadolinium. MRI was performed on ex vivo tissue specimens at 7 T at a spatial resolution approximating plaque size (62.5 μm3), in order to prove the concept that the probe, when administered intravenously, can selectively enhance plaques. The plaque-to-background tissue contrast-to-noise ratio, which was precisely correlated with histologically stained plaques, was enhanced more than nine-fold in regions of cortex and hippocampus following intravenous administration of this probe in AD transgenic mice. Continuing engineering efforts to improve spatial resolution are underway in MRI, which may enable in vivo imaging at the resolution of individual plaques with this or similar contrast probes. This could enable early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.",
author = "Poduslo, {Joseph F.} and Wengenack, {Thomas M.} and Curran, {Geoffry L.} and Thomas Wisniewski and Sigurdsson, {Einar M.} and Macura, {Slobodan I} and Borowski, {Bret J.} and Jack, {Clifford R Jr.}",
year = "2002",
doi = "10.1006/nbdi.2002.0550",
language = "English (US)",
volume = "11",
pages = "315--329",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging

AU - Poduslo, Joseph F.

AU - Wengenack, Thomas M.

AU - Curran, Geoffry L.

AU - Wisniewski, Thomas

AU - Sigurdsson, Einar M.

AU - Macura, Slobodan I

AU - Borowski, Bret J.

AU - Jack, Clifford R Jr.

PY - 2002

Y1 - 2002

N2 - Smart molecular probes for both diagnostic and therapeutic purposes are expected to provide significant advances in clinical medicine and biomedical research. We describe such a probe that targets β-amyloid plaques of Alzheimer's disease and is detectable by magnetic resonance imaging (MRI) because of contrast imparted by gadolinium labeling. Three properties essential for contrast enhancement of β-amyloid plaques on MRI exist in this smart molecular probe, putrescine-gadolinium-amyloid-β peptide: (1) transport across the blood-brain barrier following intravenous injection conferred by the polyamine moiety, (2) binding to plaques with molecular specificity by putrescine-amyloid-β, and (3) magnetic resonance imaging contrast by gadolinium. MRI was performed on ex vivo tissue specimens at 7 T at a spatial resolution approximating plaque size (62.5 μm3), in order to prove the concept that the probe, when administered intravenously, can selectively enhance plaques. The plaque-to-background tissue contrast-to-noise ratio, which was precisely correlated with histologically stained plaques, was enhanced more than nine-fold in regions of cortex and hippocampus following intravenous administration of this probe in AD transgenic mice. Continuing engineering efforts to improve spatial resolution are underway in MRI, which may enable in vivo imaging at the resolution of individual plaques with this or similar contrast probes. This could enable early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.

AB - Smart molecular probes for both diagnostic and therapeutic purposes are expected to provide significant advances in clinical medicine and biomedical research. We describe such a probe that targets β-amyloid plaques of Alzheimer's disease and is detectable by magnetic resonance imaging (MRI) because of contrast imparted by gadolinium labeling. Three properties essential for contrast enhancement of β-amyloid plaques on MRI exist in this smart molecular probe, putrescine-gadolinium-amyloid-β peptide: (1) transport across the blood-brain barrier following intravenous injection conferred by the polyamine moiety, (2) binding to plaques with molecular specificity by putrescine-amyloid-β, and (3) magnetic resonance imaging contrast by gadolinium. MRI was performed on ex vivo tissue specimens at 7 T at a spatial resolution approximating plaque size (62.5 μm3), in order to prove the concept that the probe, when administered intravenously, can selectively enhance plaques. The plaque-to-background tissue contrast-to-noise ratio, which was precisely correlated with histologically stained plaques, was enhanced more than nine-fold in regions of cortex and hippocampus following intravenous administration of this probe in AD transgenic mice. Continuing engineering efforts to improve spatial resolution are underway in MRI, which may enable in vivo imaging at the resolution of individual plaques with this or similar contrast probes. This could enable early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.

UR - http://www.scopus.com/inward/record.url?scp=0036965918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036965918&partnerID=8YFLogxK

U2 - 10.1006/nbdi.2002.0550

DO - 10.1006/nbdi.2002.0550

M3 - Article

C2 - 12505424

AN - SCOPUS:0036965918

VL - 11

SP - 315

EP - 329

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 2

ER -